@article{vanDintherZhangWeidaueretal.2013,
  author    = {van Dinther, Maarten and Zhang, Juan and Weidauer, Stella E. and Boschert, Verena and Muth, Eva-Maria and Knappik, Achim and de Gorter, David J. J. and van Kasteren, Puck B. and Frisch, Christian and M{\"u}ller, Thomas D. and ten Dijke, Peter},
  title     = {Anti-Sclerostin Antibody Inhibits Internalization of Sclerostin and Sclerostin-Mediated Antagonism of Wnt/LRP6 Signaling},
  series = {PLoS ONE},
  volume    = {8},
  journal   = {PLoS ONE},
  number    = {4},
  doi       = {10.1371/journal.pone.0062295},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-130981},
  pages     = {e62295},
  year      = {2013},
  abstract  = {Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of osteoporosis. The exact molecular mechanism by which Sclerostin exerts its antagonistic effects on Wnt signaling in bone forming osteoblasts remains unclear. Here we show that Wnt3a-induced transcriptional responses and induction of alkaline phosphatase activity, an early marker of osteoblast differentiation, require the Wnt co-receptors LRP5 and LRP6. Unlike Dickkopf1 (DKK1), Sclerostin does not inhibit Wnt-3a-induced phosphorylation of LRP5 at serine 1503 or LRP6 at serine 1490. Affinity labeling of cell surface proteins with \([^{125} I]\) Sclerostin identified LRP6 as the main specific Sclerostin receptor in multiple mesenchymal cell lines. When cells were challenged with Sclerostin fused to recombinant green fluorescent protein (GFP) this was internalized, likely via a Clathrin-dependent process, and subsequently degraded in a temperature and proteasome-dependent manner. Ectopic expression of LRP6 greatly enhanced binding and cellular uptake of Sclerostin-GFP, which was reduced by the addition of an excess of non-GFP-fused Sclerostin. Finally, an anti-Sclerostin antibody inhibited the internalization of Sclerostin-GFP and binding of Sclerostin to LRP6. Moreover, this antibody attenuated the antagonistic activity of Sclerostin on canonical Wnt-induced responses.},
  language  = {en}
}
@article{AeschlimannBrixnerCinchettietal.2017,
  author    = {Aeschlimann, Martin and Brixner, Tobias and Cinchetti, Mirko and Frisch, Benjamin and Hecht, Bert and Hensen, Matthias and Huber, Bernhard and Kramer, Christian and Krauss, Enno and Loeber, Thomas H. and Pfeiffer, Walter and Piecuch, Martin and Thielen, Philip},
  title     = {Cavity-assisted ultrafast long-range periodic energy transfer between plasmonic nanoantennas},
  series = {Light: Science \& Applications},
  volume    = {6},
  journal   = {Light: Science \& Applications},
  doi       = {10.1038/lsa.2017.111},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-173265},
  year      = {2017},
  abstract  = {Radiationless energy transfer is at the core of diverse phenomena, such as light harvesting in photosynthesis\(^1\), energy-transfer-based microspectroscopies\(^2\), nanoscale quantum entanglement\(^3\) and photonic-mode hybridization\(^4\). Typically, the transfer is efficient only for separations that are much shorter than the diffraction limit. This hampers its application in optical communication and quantum information processing, which require spatially selective addressing. Here, we demonstrate highly efficient radiationless coherent energy transfer over a distance of twice the excitation wavelength by combining localized and delocalized\(^5\) plasmonic modes. Analogous to the Tavis-Cummings model, two whispering-gallery-mode antennas\(^6\) placed in the foci of an elliptical plasmonic cavity\(^7\) fabricated from single-crystal gold plates act as a pair of oscillators coupled to a common cavity mode. Time-resolved two-photon photoemission electron microscopy (TR 2P-PEEM) reveals an ultrafast long-range periodic energy transfer in accordance with the simulations. Our observations open perspectives for the optimization and tailoring of mesoscopic energy transfer and long-range quantum emitter coupling.},
  language  = {en}
}
@article{PetersFrischStocketal.2022,
  author    = {Peters, Sarah and Frisch, Sabine and Stock, Annika and Merta, Julien and B{\"a}umer, Christian and Blase, Christoph and Schuermann, Eicke and Tippelt, Stephan and Bison, Brigitte and Fr{\"u}hwald, Michael and Rutkowski, Stefan and Fleischhack, Gudrun and Timmermann, Beate},
  title     = {Proton beam therapy for pediatric tumors of the central nervous system — experiences of clinical outcome and feasibility from the KiProReg study},
  series = {Cancers},
  volume    = {14},
  journal   = {Cancers},
  number    = {23},
  issn      = {2072-6694},
  doi       = {10.3390/cancers14235863},
  url       = {http://nbn-resolving.de/urn:nbn:de:bvb:20-opus-297489},
  year      = {2022},
  abstract  = {As radiotherapy is an important part of the treatment in a variety of pediatric tumors of the central nervous system (CNS), proton beam therapy (PBT) plays an evolving role due to its potential benefits attributable to the unique dose distribution, with the possibility to deliver high doses to the target volume while sparing surrounding tissue. Children receiving PBT for an intracranial tumor between August 2013 and October 2017 were enrolled in the prospective registry study KiProReg. Patient's clinical data including treatment, outcome, and follow-up were analyzed using descriptive statistics, Kaplan-Meier, and Cox regression analysis. Adverse events were scored according to the Common Terminology Criteria for Adverse Events (CTCAE) 4.0 before, during, and after PBT. Written reports of follow-up imaging were screened for newly emerged evidence of imaging changes, according to a list of predefined keywords for the first 14 months after PBT. Two hundred and ninety-four patients were enrolled in this study. The 3-year overall survival of the whole cohort was 82.7\%, 3-year progression-free survival was 67.3\%, and 3-year local control was 79.5\%. Seventeen patients developed grade 3 adverse events of the CNS during long-term follow-up (new adverse event n = 7; deterioration n = 10). Two patients developed vision loss (CTCAE 4°). This analysis demonstrates good general outcomes after PBT.},
  language  = {en}
}